Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Short-term Investments (2022 - 2025)

Harmony Biosciences Holdings' Short-term Investments history spans 4 years, with the latest figure at $22.8 million for Q4 2025.

  • For Q4 2025, Short-term Investments rose 61.0% year-over-year to $22.8 million; the TTM value through Dec 2025 reached $22.8 million, up 61.0%, while the annual FY2025 figure was $22.8 million, 61.0% up from the prior year.
  • Short-term Investments for Q4 2025 was $22.8 million at Harmony Biosciences Holdings, down from $25.6 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $79.3 million in Q4 2022 and bottomed at $14.2 million in Q4 2024.
  • The 4-year median for Short-term Investments is $29.6 million (2024), against an average of $35.5 million.
  • The largest annual shift saw Short-term Investments surged 203.71% in 2023 before it plummeted 66.06% in 2024.
  • A 4-year view of Short-term Investments shows it stood at $79.3 million in 2022, then plummeted by 47.31% to $41.8 million in 2023, then tumbled by 66.06% to $14.2 million in 2024, then surged by 61.0% to $22.8 million in 2025.
  • Per Business Quant, the three most recent readings for HRMY's Short-term Investments are $22.8 million (Q4 2025), $25.6 million (Q3 2025), and $19.2 million (Q2 2025).